Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies. (Q55296113)

From Wikidata

Jump to navigation Jump to search

scientific article published on 27 February 2017

Language	Label	Description	Also known as
English	Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies.	scientific article published on 27 February 2017

Statements

scholarly article

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

Effects of a sodium-glucose cotransporter 2 inhibitor in nonalcoholic fatty liver disease complicated by diabetes mellitus: Preliminary prospective study based on serial liver biopsies. (English)

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

fatty liver disease

1 reference

based on heuristic

inferred from title

metabolic dysfunction–associated steatotic liver disease

1 reference

based on heuristic

inferred from title

Hiromitsu Kumada

14

object named as

Hiromitsu Kumada

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

Fumitaka Suzuki

12

object named as

Fumitaka Suzuki

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

13

object named as

Kenji Ikeda

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

Masahiro Kobayashi

9

object named as

Masahiro Kobayashi

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

Yoshiyuki Suzuki

11

object named as

Yoshiyuki Suzuki

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

1

object named as

Norio Akuta

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

4

object named as

Yasuji Arase

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

7

object named as

Hitomi Sezaki

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

5

object named as

Satoshi Saitoh

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

Yusuke Kawamura

3

object named as

Yusuke Kawamura

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

Mariko Kobayashi

10

object named as

Mariko Kobayashi

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

8

object named as

Tetsuya Hosaka

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

Shunichiro Fujiyama

6

object named as

Shunichiro Fujiyama

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

author name string

Chizuru Watanabe

2

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

publication date

27 February 2017

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

Hepatology Communications

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

1

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

46-52

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

1

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in Japan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

3 July 2018

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

3 July 2018

Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

3 July 2018

Limitations of liver biopsy and non-invasive diagnostic tests for the diagnosis of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

3 July 2018

Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

3 July 2018

Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

3 July 2018

Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

3 July 2018

Circulating microRNAs in patients with chronic hepatitis C and non-alcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

3 July 2018

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

3 July 2018

Global challenges in liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

3 July 2018

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

3 July 2018

Nonalcoholic fatty liver disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

3 July 2018

Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

3 July 2018

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

3 July 2018

Ipragliflozin, an SGLT2 inhibitor, exhibits a prophylactic effect on hepatic steatosis and fibrosis induced by choline-deficient l-amino acid-defined diet in rats.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

12 August 2018

Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

12 August 2018

Associations between circulating microRNAs (miR-21, miR-34a, miR-122 and miR-451) and non-alcoholic fatty liver.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

12 August 2018

Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

12 August 2018

Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

12 August 2018

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

12 August 2018

Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5747031

12 August 2018

Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2, dose dependently reduces calculated renal threshold for glucose excretion and increases urinary glucose excretion in healthy subjects

1 reference

https://api.crossref.org/works/10.1002%2FHEP4.1019

7 January 2021

based on heuristic

inferred from DOI database lookup

Determination of reliability criteria for liver stiffness evaluation by transient elastography

1 reference

https://api.crossref.org/works/10.1002%2FHEP4.1019

7 January 2021

based on heuristic

inferred from DOI database lookup

Appropriate use of virtual touch quantification and FibroScan M and XL probes according to the skin capsular distance

1 reference

https://api.crossref.org/works/10.1002%2FHEP4.1019

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/HEP4.1019

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

1 reference

Europe PubMed Central

30 June 2018

http://europepmc.org/abstract/PMC/5747031

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q55296113&oldid=1882916843"